{"disease":{"id":"head-and-neck-neoplasms","name":"head and neck neoplasms"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04075305","title":"The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","phase":"","overall_status":"RECRUITING","enrollment_count":8000,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT06335342","title":"Radiotherapy Treatments for Neoplasms in the Head and Neck Region","phase":"","overall_status":"UNKNOWN","enrollment_count":4050,"lead_sponsor_name":"European Institute of Oncology","has_results":false},{"nct_id":"NCT02017288","title":"Study to Evaluate the Natural History of Head and Neck Cancer Precursors in Taiwan","phase":"","overall_status":"COMPLETED","enrollment_count":3576,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04389632","title":"A Study of Sigvotatug Vedotin in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1006,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT06303180","title":"NIDCD Otolaryngology Clinical Protocol Biospecimen Bank","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"National Institute on Deafness and Other Communication Disorders (NIDCD)","has_results":false},{"nct_id":"NCT03429036","title":"Biospecimen Procurement for Head and Neck Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04895709","title":"A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":949,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT03040999","title":"Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":804,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03546322","title":"Customized Registry Tool for Tracking Adherence to Clinical Guidelines for Head and Neck Cancers","phase":"","overall_status":"COMPLETED","enrollment_count":802,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT06840639","title":"The Impact of Dental Health on Complications During and Following Radiotherapy in the Head and Neck Region.","phase":"","overall_status":"COMPLETED","enrollment_count":750,"lead_sponsor_name":"Lund University Hospital","has_results":false},{"nct_id":"NCT05208762","title":"A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":714,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT03765918","title":"Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":714,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT01345669","title":"LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":617,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT05007106","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":613,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03037385","title":"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":590,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT02568267","title":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":534,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT03343236","title":"Nutrition and Inflammation in Patients With Head and Neck Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":522,"lead_sponsor_name":"Uppsala University","has_results":false},{"nct_id":"NCT01631552","title":"Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":515,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT03942380","title":"Cell-free Tumor DNA in Head and Neck Cancer Patients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Christian von Buchwald","has_results":false},{"nct_id":"NCT01345682","title":"LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":483,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT06356272","title":"Oropharynx (OPX) Biomarker Trial","phase":"","overall_status":"RECRUITING","enrollment_count":440,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05647122","title":"First in Human Study of AZD9592 in Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":403,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05811936","title":"The SNAP Tool for Head and Neck Cancer Survivor-Caregiver Dyads","phase":"NA","overall_status":"RECRUITING","enrollment_count":352,"lead_sponsor_name":"Medical University of South Carolina","has_results":false},{"nct_id":"NCT01856478","title":"LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":340,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT04429542","title":"Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":292,"lead_sponsor_name":"Bicara Therapeutics","has_results":false},{"nct_id":"NCT04697446","title":"External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC","phase":"","overall_status":"UNKNOWN","enrollment_count":279,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT03012581","title":"Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":269,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT04758026","title":"H&N Cancer; Survivorship and Late Effects","phase":"","overall_status":"COMPLETED","enrollment_count":265,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT00100204","title":"Salivary Proteins in Disease and Health","phase":"","overall_status":"COMPLETED","enrollment_count":264,"lead_sponsor_name":"National Institute of Dental and Craniofacial Research (NIDCR)","has_results":false},{"nct_id":"NCT04435964","title":"Gender Difference in sidE eFfects of ImmuNotherapy: a Possible Clue to Optimize cancEr tReatment","phase":"","overall_status":"COMPLETED","enrollment_count":247,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT00995293","title":"Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":240,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT04222972","title":"A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":223,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT00568490","title":"Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT03678649","title":"A Prospective Randomized Trial of Capecitabine Treatment in Patients With HNSCC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":180,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT03292250","title":"Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":180,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT02376699","title":"Safety Study of SEA-CD40 in Cancer Patients","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":159,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT03672799","title":"Rehabilitation Planning Consult Phase II Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT03517488","title":"A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT04117139","title":"The Diagnostic Value of PET/MRI in Head and Neck Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":142,"lead_sponsor_name":"Odense University Hospital","has_results":false},{"nct_id":"NCT05544929","title":"A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":126,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06662929","title":"Arabic PRO Measures for Head and Neck Cancer Radiotherapy.","phase":"","overall_status":"RECRUITING","enrollment_count":125,"lead_sponsor_name":"King Saud University","has_results":false},{"nct_id":"NCT06003231","title":"A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT05022667","title":"Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy","phase":"NA","overall_status":"COMPLETED","enrollment_count":114,"lead_sponsor_name":"University of Michigan","has_results":true},{"nct_id":"NCT07158164","title":"DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":false},{"nct_id":"NCT02573493","title":"Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT04598087","title":"Prehabilitation and Recovery After Head and Neck Cancer Surgery","phase":"NA","overall_status":"UNKNOWN","enrollment_count":96,"lead_sponsor_name":"University of Calgary","has_results":false},{"nct_id":"NCT04878692","title":"Evaluation of a Cosmetic Product to Preserve Skin Conditions When Using Anti-EGFR Cancer Therapies","phase":"NA","overall_status":"UNKNOWN","enrollment_count":96,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT00978250","title":"A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04260126","title":"Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"PDS Biotechnology Corp.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}